Update on tenofovir toxicity in the kidney

Pediatric Nephrology

Volumn 28, Issue 7, 2013, Pages 1011-1023

  Hall, Andrew M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B; HIV; Proximal tubule; Renal Fanconi syndrome; Tenofovir

Indexed keywords

ATAZANAVIR; CIMETIDINE; CREATININE; DARUNAVIR; DIDANOSINE; LOPINAVIR; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITONAVIR; STAVUDINE; TENOFOVIR; TRIMETHOPRIM; ZIDOVUDINE;

BONE DENSITY; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ELECTRON MICROSCOPY; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; IN VITRO STUDY; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LONG TERM CARE; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HEPATITIS B; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY DISEASES; ORGANOPHOSPHONATES; RISK FACTORS;

EID: 84878646316     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2269-7     Document Type: Review

References (113)

1. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G (2003) Drug-induced Fanconi's syndrome. Am J Kidney Dis 41:292-309
2. Izzedine H, Harris M, Perazella MA (2009) The nephrotoxic effects of HAART. Nat Rev Nephrol 5:563-573
3. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51:496-505
4. Jao J, Wyatt CM (2010) Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 17:72-82
5. Perazella MA (2010) Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 78:1060-1063
6. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V (2010) Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 9:545-559
7. Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57:773-780
8. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A (2011) Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011:354908
9. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201
10. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22:2155-2163
11. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B (2004) Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 37:1489-1495
12. Gallant JE, Parish MA, Keruly JC, Moore RD (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40:1194-1198
13. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7:105-111
14. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H (2007) Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12:1165-1173
15. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, Brooks JT, HIV OS, I (2007) Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic) 6:178-187
16. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197:102-108
17. Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabie A, Poizot-Martin I, Katlama C, Brunet-Francois C, Yazdanpanah Y, Dellamonica P (2011) Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 6:1700-1707
18. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26:867-875
19. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21:1273-1281
20. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA (2011) Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant 26:2291-2297
21. Kohler JJ, Hosseini SH, Hoying-Brandt A, Green E, Johnson DM, Russ R, Tran D, Raper CM, Santoianni R, Lewis W (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89:513-519
22. Liborio AB, Andrade L, Pereira LV, Sanches TR, Shimizu MH, Seguro AC (2008) Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int 74:910-918
23. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA (2009) Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr 51:258-263
24. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG, Von MW, Allen PC, Valverde C, Castillo AB, Martin RB, Samii VF, Bendele R, Desjardins J, Marthas ML, Pedersen NC, Bischofberger N (2004) Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48:1469-1487
25. de la Prada FJ, Prados AM, Tugores A, Uriol M, Saus C, Morey A (2006) Acute renal failure and proximal renal tubular dysfunction in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia 26:626-630
26. Malik A, Abraham P, Malik N (2005) Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J Infect 51:E61-E65
27. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35:269-273
28. Quimby D, Brito MO (2005) Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read 15:357-364
29. Rifkin BS, Perazella MA (2004) Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 117:282-284
30. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10:482-487
31. Agarwala R, Mohan S, Herlitz LC, Cheng JT (2010) The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity. Kidney Int 77:475-476
32. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS (2010) Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78:1171-1177
33. Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, Tanuma J, Yazaki H, Ueda A, Kimura S, Oka S (2006) Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22:744-748
34. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, Unwin RJ, Williams IG (2009) Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 54:1034-1042
35. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, Vispo E, Soriano V (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23:689-696
36. Dauchy FA, Lawson-Ayayi S, de La FR, Bonnet F, Rigothier C, Mehsen N, Miremont-Salame G, Cazanave C, Greib C, Dabis F, Dupon M (2011) Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 80:302-309
37. Kinai E, Hanabusa H (2005) Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 19:2031-2033
38. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D (2010) Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53:62-69
39. Calza L, Trapani F, Tedeschi S, Piergentili B, Manfredi R, Colangeli V, Viale P (2011) Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand J Infect Dis 43:656-660
40. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML (2010) Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55:49-57
41. Arribas JR, Pozniak AL, Gallant JE, DeJesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47:74-78
42. Vrouenraets SM, Fux CA, Wit FW, Garcia EF, Furrer H, Brinkman K, Hoek FJ, Abeling NG, Krediet RT, Reiss P (2011) Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 25:2149-2155
43. Vallon V, Eraly SA, Ramachandra RS, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK, Rieg T (2012) A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol 302:F1293-F1299
44. Cihlar T, Ho ES, Lin DC, Mulato AS (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648
45. Gupta SK (2008) Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 22:99-103
46. Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A (2006) Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 7:451-456
47. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercie P, Morlat P, Thiebaut R, Dabis F (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22:395-402
48. Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, Blanchet F, Peytavin G, Leport C (2007) Is phosphatemia the best tool to monitor renal tenofovir toxicity? J Acquir Immune Defic Syndr 46:256-258
49. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H (2008) Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 13:1077-1082
50. Wesseling-Perry K (2010) FGF-23 in bone biology. Pediatr Nephrol 25:603-608
51. Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier MC (2011) Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78:306-308
52. Haverkort ME, van der Spek BW, Lips P, Slieker WA, ter Heine R, Huitema AD, Bronsveld W (2011) Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis 43:821-826
53. Bech A, Van BP, Nabbe K, Gisolf J, Richter C, De BH (2012) Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir. HIV Med. doi: 10.1111/j.1468-1293.2012.01015.x
54. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52:3144-3160
55. Rodriguez-Novoa S, Labarga P, D'avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di PG, Soriano V (2010) Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 24:1064-1066
56. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, Gonzalez-Pardo G, Khoo S, Back D, Owen A (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48:e108-e116
57. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S (2011) Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One 6:e22661
58. Gilead Sciences (2011) Viread product monograph
59. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627
60. Rodriguez-Novoa S, Labarga P, Soriano V (2009) Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10:1675-1685
61. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV (2008) Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47:298-303
62. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG (2006) Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194:1481-1491
63. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di PG, Back DJ, Khoo S, Pirmohamed M, Owen A (2011) Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 204:145-153
64. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV (2008) The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83:265-272
65. Gallant JE, Moore RD (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23:1971-1975
66. Moyle G (2005) Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 10(Suppl 2):M47-M52
67. Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46:716-723
68. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ (2002) Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 54:37-45
69. Biesecker G, Karimi S, Desjardins J, Meyer D, Abbott B, Bendele R, Richardson F (2003) Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 58:217-225
70. Cote HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS (2006) Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 11:79-86
71. Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GF, Angarano G (2012) Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS 26:5-11
72. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL (2005) Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 116:e846-e854
73. Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, Beretta S, Rombola G, Mora S (2007) Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 27:573-581
74. Papaleo A, Warszawski J, Salomon R, Jullien V, Veber F, Dechaux M, Blanche S (2007) Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J 26:949-951
75. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, Menson E, Butler K, Gibb D (2009) Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 28:204-209
76. Judd A, Boyd KL, Stohr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM (2010) Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24:525-534
77. Soler-Palacin P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, Mellado MJ, Garcia L, Uriona S, Martin-Nalda A, Figueras C (2011) Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 25:171-176
78. Vigano A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, Penagini F, Caprio C, Zuccotti GV (2011) Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig 31:407-415
79. Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S (2012) Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis 12:18
80. Hussain S, Khayat A, Tolaymat A, Rathore MH (2006) Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 21:1034-1036
81. Hawkins S, Ball C (2007) Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 8:411
82. Wood SM, Shah SS, Steenhoff AP, Meyers KE, Kaplan BS, Rutstein RM (2009) Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDS 23:1-4
83. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL (2006) Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118:e711-e718
84. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R (2008) Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 152:582-584
85. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A (2005) A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 40:448-450
86. Vigano A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, Fabiano V, Giacomet V, Mora S (2010) Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther 15:1053-1058
87. Wools-Kaloustian KK, Gupta SK (2008) Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell. Kidney Int 74:845-847
88. Msango L, Downs JA, Kalluvya SE, Kidenya BR, Kabangila R, Johnson WD Jr, Fitzgerald DW, Peck RN (2011) Renal dysfunction among HIV-infected patients starting antiretroviral therapy. AIDS 25:1421-1425
89. Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, Kigozi A, Buchacz K, Weidle PJ (2008) Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 74:925-929
90. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, Stringer EM, Krishnasami Z, Mwinga A, Saag MS, Stringer JS, Chi BH (2008) Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 22:1821-1827
91. Stohr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, Gibb DM, Hakim J (2011) Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther 16:1011-1020
92. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS (2010) Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 54:63-70
93. Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Trivino L, Makakole L, Ford N (2011) Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One 6:e17609
94. Manosuthi W, Prasithsirikul W, Tantanathip P, Chimsuntorn S, Nilkamhang S, Sungkanuparph S (2011) Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. Southeast Asian J Trop Med Public Health 42:643-650
95. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.
96. Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442-2455
97. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132-143
98. Si-Ahmed SN, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, Deterding K, Dumortier J, Bailly F, Esteban R, Wedemeyer H, Janssen HL, Zoulim F (2011) Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res 92:90-95
99. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E (2011) Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 55:1235-1240
100. Samarawickrama A, Cai M, Smith E, Nambiar K, Sabin C, Fisher M, Gilleece Y, Holt S (2012) Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. doi: 10.1111/j.1468-1293.2012.01003.x
101. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40:1559-1585
102. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W (2011) Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91:852-858
103. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126:257-263
104. Izzedine H, Thibault V, Valantin MA, Peytavin G, Schneider L, Benhamou Y (2010) Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence? AIDS 24:1078-1079
105. Robbins N, Koch SE, Tranter M, Rubinstein J (2012) The history and future of probenecid. Cardiovasc Toxicol 12:1-9
106. Guan Y (2004) Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15:2801-2815
107. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411-418
108. Cihlar T, Laflamme G, Fisher R, Carey AC, Vela JE, Mackman R, Ray AS (2009) Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother 53:150-156
109. Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW Jr, Mankowski MK, Osterling MC, Almond MR, Painter GR (2010) Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother 54:2901-2909
110. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G (2004) Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18:1074-1076
111. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G (2006) Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42:283-290
112. Wever K, van Agtmael MA, Carr A (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55:78-81
113. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG (2010) Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121:651-658